Items Tagged ‘CML’

June 14th, 2017

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia

By

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients with the condition and, in many ways, ushered in the era of molecularly-targeted treatments against cancer. […]

View full entry

Tags: BCR-ABL, Chronic Myeloid Leukemia, CML, dasatinib), Gleevec, imatinib, Leukemia, News, Philadelphia chromosome Sprycel


December 14th, 2016

FDA Grants Iclusig® Expanded Approval for CML

By

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, CML, Iclusig, Leukemia, News, PACE trial, Ph+ ALL, ponatinib, TKI, tyrosine kinase inhibitor


April 7th, 2015

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia

By

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.  These data are consistent with that […]

View full entry

Tags: Chronic Myeloid Leukemia, CML, ENESTnd trial, Gleevec, imatinib, Leukemia, News, nilotinib, Philadelphia chromosome positive, Tasigna